Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD22/CD19 Dual-Target CAR-T Cell Therapy for Standard-risk B-ALL Consolidation
NCT07575919Phase 2Recruiting
- Sponsor
- Liping Dou
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD22/CD19 dual-target CAR-T cells in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Liping Dou. Started Jan 2026; status: recruiting.
02
Drugs
CD22/CD19 dual-target CAR-T cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07575919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07575919.